CN113238058B - Method for evaluating CAR-T treatment initiation T cells - Google Patents
Method for evaluating CAR-T treatment initiation T cells Download PDFInfo
- Publication number
- CN113238058B CN113238058B CN202110452520.6A CN202110452520A CN113238058B CN 113238058 B CN113238058 B CN 113238058B CN 202110452520 A CN202110452520 A CN 202110452520A CN 113238058 B CN113238058 B CN 113238058B
- Authority
- CN
- China
- Prior art keywords
- cells
- car
- test result
- content
- preset model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 151
- 238000011282 treatment Methods 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 24
- 230000000977 initiatory effect Effects 0.000 title claims abstract description 23
- 238000012360 testing method Methods 0.000 claims abstract description 51
- 238000001514 detection method Methods 0.000 claims abstract description 35
- 210000003289 regulatory T cell Anatomy 0.000 claims abstract description 34
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims abstract description 32
- 102000001398 Granzyme Human genes 0.000 claims abstract description 30
- 108060005986 Granzyme Proteins 0.000 claims abstract description 30
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229930192851 perforin Natural products 0.000 claims abstract description 29
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 29
- 239000011886 peripheral blood Substances 0.000 claims abstract description 29
- 102000008096 B7-H1 Antigen Human genes 0.000 claims abstract 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims abstract 4
- 238000000684 flow cytometry Methods 0.000 claims description 35
- 238000012549 training Methods 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 abstract description 74
- 210000002865 immune cell Anatomy 0.000 abstract description 14
- 238000002659 cell therapy Methods 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 239000003219 hemolytic agent Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 238000011467 adoptive cell therapy Methods 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108091007744 Programmed cell death receptors Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110452520.6A CN113238058B (en) | 2021-04-26 | 2021-04-26 | Method for evaluating CAR-T treatment initiation T cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110452520.6A CN113238058B (en) | 2021-04-26 | 2021-04-26 | Method for evaluating CAR-T treatment initiation T cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113238058A CN113238058A (en) | 2021-08-10 |
CN113238058B true CN113238058B (en) | 2022-06-28 |
Family
ID=77129437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110452520.6A Active CN113238058B (en) | 2021-04-26 | 2021-04-26 | Method for evaluating CAR-T treatment initiation T cells |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113238058B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112218888A (en) * | 2018-04-12 | 2021-01-12 | 凯德药业股份有限公司 | Chimeric receptor T cell therapy using characteristics of tumor microenvironment |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200061113A1 (en) * | 2018-04-12 | 2020-02-27 | Novartis Ag | Chimeric antigen receptor therapy characterization assays and uses thereof |
-
2021
- 2021-04-26 CN CN202110452520.6A patent/CN113238058B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112218888A (en) * | 2018-04-12 | 2021-01-12 | 凯德药业股份有限公司 | Chimeric receptor T cell therapy using characteristics of tumor microenvironment |
Non-Patent Citations (2)
Title |
---|
CD19 CAR-T 细胞治疗复发/难治性B-ALL后细胞因子水平变化及其临床意义;张秋叶 等;《中国免疫学杂志》;20191231;第35卷(第19期);2385-2390 * |
Immune cells within the tumor microenvironment: biological functions and roles in;Xu Lei 等;《Journal Pre-proof》;20191231;第21卷 * |
Also Published As
Publication number | Publication date |
---|---|
CN113238058A (en) | 2021-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Duffy et al. | Standardized whole blood stimulation improves immunomonitoring of induced immune responses in multi-center study | |
CN101027557B (en) | Whole blood preparation for cytometric analysis of cell signaling pathways | |
Gaines et al. | A new method for measuring lymphoproliferation at the single-cell level in whole blood cultures by flow cytometry | |
EP2694962B1 (en) | Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same | |
Choi et al. | Diagnostic value of peripheral blood immune profiling in colorectal cancer | |
CN107860924B (en) | Application of the novel gamma delta T cells in preparation assessment AML curative effect reagent box | |
US20120083007A1 (en) | Basophil Activation Based Allergy Diagnostic Test | |
KR102268963B1 (en) | A method and kit for cancer diagnostics or predict response to treatment by evaluating cancer immunity in peripheral blood by machine learning technique | |
Throm et al. | Identification of enhanced IFN-γ signaling in polyarticular juvenile idiopathic arthritis with mass cytometry | |
EP1019546B1 (en) | Methods for measurement of lymphocyte function | |
CN113125755A (en) | 9 antibody kit for monitoring human immune state and application thereof | |
US20200011865A1 (en) | Methods and kits for detecting basophil activation | |
Aljadi et al. | A novel tool for clinical diagnosis of allergy operating a microfluidic immunoaffinity basophil activation test technique | |
CN113125733A (en) | 42 antibody kit for monitoring human immune state and application thereof | |
CN113238058B (en) | Method for evaluating CAR-T treatment initiation T cells | |
US5968755A (en) | Methods for determining T-cell profiles of immunocompromised subjects | |
Johansson et al. | Detection of CAR‐T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories | |
Sponaugle et al. | OMIP‐087: Thirty‐two parameter mass cytometry panel to assess human CD4 and CD8 T cell activation, memory subsets, and helper subsets | |
JP7175068B2 (en) | Biomarkers for predicting response to cancer therapy | |
Fleisher et al. | Introduction to diagnostic laboratory immunology | |
CN113109575A (en) | 40 antibody kit for monitoring human immune state and application | |
Cooksey et al. | Natural killer cells in renal allograft rejection | |
JP6206953B2 (en) | Method for testing the likelihood of developing adult T-cell leukemia | |
Hutchinson et al. | Mitogen‐induced T‐cell CD69 expression is a less sensitive measure of T‐cell function than [3H]‐thymidine uptake | |
CA2521486A1 (en) | Method of analysing the cytoskeletal protein of cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhai Zhimin Inventor after: Wang Huiping Inventor after: Pu Lianfang Inventor before: Zhai Zhimin |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240718 Address after: 503, West Side of Building D1-3A, Optics Valley Bio City Innovation Park, No. 666 Gaoxin Avenue, Jiufeng Street, Donghu New Technology Development Zone, Wuhan City, Hubei Province 430000 Patentee after: Wuhan Hongmeng Saier Biotechnology Co.,Ltd. Country or region after: China Address before: 230601 Furong Road 678, Hefei Economic and Technological Development Zone, Anhui Province Patentee before: THE SECOND HOSPITAL OF ANHUI MEDICAL University Country or region before: China Patentee before: Lu Chao |